References
- V. J. Hall, S. Foulkes, A. Saei, N. Andrews, B. Oguti, A. Charlett, E. Wellington, J. Stowe, N. Gillson, A. Atti, J. Islam, I. Karagiannis, K. Munro, J. Khawam, M. A. Chand, C. S. Brown, M. Ramsay, J. Lopez-Bernal, S. Hopkins, and SIREN study group, COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study, Lancet (London) 397(10286) (2021) 1725–1735; https://doi.org/10.1016/S0140-6736(21)00790-X
- J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang and B. F. Pierce, Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape, Nat. Rev. Immunol. 21(10) (2021) 626–636; https://doi.org/10.1038/s41577-021-00592-1
- A. Kazak, S. Hintistan and Ö. Betül, Dünyada ve Türkiye’de COVID-19 aşı geliştirme çalışmaları (COVID-19 vaccine development studies in the world and in Turkey), Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi (J. Celal Bayar Uni. Health Sci. Inst.) 7(4) (2020) 571–575; https://doi.org/10.348087/cbusbed.749009
- M. D. Tanrıöver, H. L. Doğanay, M. Akova, H. R. Güner, A. Azap, S. Akhan, Ş. Köse, F. Ş. Erdinç, E. H. Akalın, Ö. F. Tabak, H. Pullukçu, Ö. Batum, S. Ş. Yavuz, Ö. Turhan, M. T. Yıldırmak, İ. Köksal, Y. Taşova, V. Korten, G. Yılmaz, M. K. Çelen, S. Altin, İ. Çelik, Y. Bayındır, İ. Karaoğlan, A. Yılmaz, A. Özkul, H. Gür, S. Unal, and the CoronaVac study group, Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey, Lancet (London) 398(10296) (2021) 213–222; https://doi.org/10.1016/S0140-6736(21)01429-X
- T. Fiolet, Y. Kherabi, C. J. MacDonald, J. Ghosn and N. Peiffer-Smadja, Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review, Clin. Microb. Infect. 28(2) (2022) 202–221; https://doi.org/10.1016/j.cmi.2021.10.005
- M. G. Thompson, J. L. Burgess, A. L. Naleway, H. L. Tyner, S. K. Yoon, J. Meece, L. E. W. Olsho, A. J. Caban-Martinez, A. Fowlkes, K. Lutrick, J. L. Kuntz, K. Dunnigan, M. J. Odean, K. T. Hegmann, E. Stefanski, L. J. Edwards, N. Schaefer-Solle, L. Grant, K. Ellingson, H. C. Groom, T. Zunie, M. S. Thiese, L. Ivacic, M. G. Wesley, J. M. Lamberte, X. Sun, M. E. Smith, A. L. Phillips, K. D. Groover, Y. M. Yoo, J. Gerald, R. T. Brown, M. K. Herring, G. Joseph, S. Beitel, T. C. Morrill, J. Mak, P. Rivers, K. M. Harris, D. R. Hunt, M. L. Arvay, P. Kutty, A. M. Fry, M. Gaglani, Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – Eight U.S. locations, December 2020-March 2021, Morb. Mortal. Weekly Rep. 70(13) (2021) 495–500; https://doi.org/10.15585/mmwr.mm7013e3
- V. Hall, S. Foulkes, F. Insalata, P. Kirwan, A. Saei, A. Atti, E. Wellington, J. Khawam, K. Munro, M. Cole, C. Tranquillini, A. Taylor-Kerr, N. Hettiarachchi, D. Calbraith, N. Sajedi, I. Milligan, Y. Themistocleous, D. Corrigan, L. Cromey, L. Price, S. Stewart, E. de Lacy, C. Norman, E. Linley, A. D. Otter, A. Semper, J. Hewson, S. D’Arcangelo, M. Chand, C. S. Brown, T. Brooks, J. Islam, A. Charlett and S. Hopkins (for the SIREN Study Group), Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection, N. Engl. J. Med. 386 (2022) 1207–1220; https://doi.org/10.1056/NEJMoa2118691
- N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A.-M. O’Connell, D. Simons, P. B. Blomquist, A. Zaidi, S. Nash, N. I. B. A. Aziz, S. Thelwall, G. Dabrera, R. Myers, G. Amirthalingam, S. Gharbia, J. C. Barrett, R. Elson, S. N. Ladhani, N. Ferguson, M. Zambon, C. N. J. Campbell, K. Brown, S. Hopkins, M. Chand, M. Ramsay and J. Lopez Bernal, Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, New Engl. J. Med. 386(16) (2022) 1532–1546; https://doi.org/10.1056/NEJMoa2119451
- European Centre for Disease Prevention and Control, Implications of the Further Emergence and Spread of the SARS CoV-2 B.1.1.529 Variant of Concern (Omicron) for the EU/EEA – first update, December 2, 2021; https://www.ecdc.europa.eu/sites/default/files/documents/threat-assessment-covid-19-emergence-sars-cov-2-variant-omicron-december-2021.pdf; last access data March 3, 2023.
- R. R. Goel, M. M. Painter, S. A. Apostolidis, D. Mathew, W. Meng, A. M. Rosenfeld, K. A. Lund-green, A. Reynaldi, D. S. Khoury, A. Pattekar, S. Gouma, L. Kuri-Cervantes, P. Hicks, S. Dysinger, A. Hicks, H. Sharma, S. Herring, S. Korte, A. E. Baxter, D. A. Oldridge, J. R. Giles, M. E. Weirick, C. M. McAllister, M. Awofolaju, N. Tanenbaum, E. M. Drapeau, J. Dougherty, S. Long, K. D’Andrea, J. T. Hamilton, M. McLaughlin, J. C. Williams, S. Adamski, O. Kuthuru, U. Penn COVID Processing Unit; I. Frank, M. R. Betts, L. A. Vella, A. Grifoni, D. Weiskopf, A. Sette, S. E. Hensley, M. P. Davenport, P. Bates, E. T. Luning Prak, A. R. Greenplate and E. J. Wherry, mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern, Science (New York) 374(6572) (2021) Article ID 1214 (17 pages); https://doi.org/10.1126/science.abm0829
- Y. M. Bar-On, Y. Goldberg, M. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. Alroy-Preis, N. Ash, R. Milo and A. Huppert, Protection of BNT162b2 vaccine booster against Covid-19 in Israel, New Engl. J. Med. 385(15) (2021) 1393–1400; https://doi.org/10.1056/NEJMoa2114255
- D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas and M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat. Med. 27(7) (2021) 1205–1211; https://doi.org/10.1038/s41591-021-01377-8
- World Health Organization, WHO COVID-19 Case Definition – Updated in Public health surveil-lance for COVID-19, WHO, 22 July 2022; https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020; last access date March 3, 2023.
- Republic of Turkey – Ministry of Health, Covid-19 Vaccine Information Platform, Covid-19 Aşısı Ulusal Uygulama Stratejisi (Covid-19 Vaccine National Implementation Strategy); https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html
- C. K. P. Mok, C. A. Cohen, S. M. S. Cheng, C. Chen, K. O. Kwok, K. Yiu, T. O. Chan, M. Bull, K. C. Ling, Z. Dai, S. S. Ng, G. C. Lui, C. Wu, G. K. Amarasinghe, D. W. Leung, S. Y. S. Wong, S. A. Valkenburg, M. Peiris and D. S. Hui, Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong, Respirology (Carlton, Vic.) 27(4) (2022) 301–310; https://doi.org/10.1111/resp.14191
- F. Rammauro, F. Carrión, N. Olivero-Deibe, M. Fló, A. Ferreira, O. Pritsch and S. Bianchi, Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2, Vaccine 40(35) (2022) 5189–5196; https://doi.org/10.1016/j.vaccine.2022.07.023
- W. W. Lim, L. Mak, G. M. Leung, B. J. Cowling and M. Peiris, Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19, Lancet Microbe 2(9) (2021) e423; https://doi.org/10.1016/S2666-5247(21)00177-4
- Y. E. Kim, K. Huh, Y. J. Park, K. R. Peck and J. Jung, Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection, JAMA 328(9) (2022) 887–889; https://doi.org/10.1001/jama.2022.12992
- J. Xie, Z. Tong, X. Guan, B. Du, H. Qiu and A. S. Slutsky, Critical care crisis and some recommendations during the COVID-19 epidemic in China, Int. Care Med. 46(5) (2020) 837–840; https://doi.org/10.1007/s00134-020-05979-7
- B. Sandalc, O. A. Uyaroğlu and G. S. Güven, COVID-19’da kronik hastalıkların rolü, önemi ve öneriler (The role and importance of chronic diseases in COVID-19 and related recommendations), Flora 25(2) (2020) 132–138; https://doi.org/10.5578/flora.69700
- Y. Zou, D. Huang, Q. Jiang, Y. Guo and C. Chen, The vaccine efficacy against the SARS-CoV-2 Omicron: A systemic review and meta-analysis, Front. Public Health 10 (2022) Article ID 940956 (9 pages); https://doi.org/10.3389/fpubh.2022.940956
- L. Wang, M. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, M. Currier, P. Shrivastava-Ranjan, B. M. Calderon, M. Sheth, B. R. Mann, J. Hossain, X. Lin, S. Lester, E. A. Pusch, J. Jones, D. Cui, P. Chatterjee, M. H. Jenks, E. K. Morantz, G. P. Larson, M. Hatta, J. L. Harcourt, A. Tamin, Y. Li, Y. Tao, K. Zhao, K. Lacek, A. Burroughs, W. Wang, M. Wilson, T. Wong, S. H. Park, S. Tong, J. R. Barnes, M. W. Tenforde, W. H. Self, N. I. Shapiro, M. C. Exline, D. C. Files, K. W. Gibbs, D. N. Hager, M. Patel, A. L. Halpin, L. K. McMullan, J. S. Lee, H. Xia, X. Xie, P.-Y. Shi, C. T. Davis, C. F. Spiropoulou, N. J. Thornburg, M. S. Oberste, V. G. Dugan, SSEV Bioinformatics Working Group, D. E. Wentworth and B. Zhou, Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines, Nature Commun. 13(1) (2022) Article ID 4350 (10 pages); https://doi.org/10.1038/s41467-022-31929-6
- M. J. Cohen, Y. Oster, A. E. Moses, A. Spitzer, S. Benenson and Israeli-Hospitals 4th Vaccine Working Group, Association of receiving a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health care workers in Israel, JAMA Network Open 5(8) (2022) e2224657 (7 pages); https://doi.org/10.1001/jamanetworkopen.2022.24657
- V. K. C. Yan, E. Y. F. Wan, X. Ye, A. H. Y. Mok, F. T. T. Lai, C. S. L. Chui, X. Li, C. K. H. Wong, P. H. Li, T. Ma, S. Qin, V. K. C. Wong, T. C. Tsang, S. H. Tsui, W. C. M. Chui, B. J. Cowling, G. M. Leung, C. S. Lau, I. C. K. Wong and E. W. Y. Chan, Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study, Emerg. Microbes Infect. 11(1) (2022) 2304–2314; https://doi.org/10.1080/22221751.2022.2 114854